NEW YORK (GenomeWeb) – Color Genomics said this week in an SEC filing that it has raised $52 million thus far in a planned $80M funding round.

A company spokesperson added today that the financing is being led by General Catalyst, and also includes Emerson Collective and CRV.

According to Color CEO Othman Laraki, money raised in the round will be used to further invest in developing testing strategies for hereditary conditions, and to further other aspects of preventive medicine — focusing on areas where "the science is clear and the results are actionable."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.